-
- Proceeds will fund Phase 2 study in thyroid eye disease (TED) with LASN01 and continue development of LASN500 in Investigational New Drug (IND) enabling studies
-
- Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease
-
- LASN01, a fully human, clinical-stage antibody which binds to IL-11R, potently blocks IL-11 signaling to prevent IL-11 driven fibrotic diseases
-
- Inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis and other fibro-inflammatory diseases
-
- Lassen to also be featured at the ATS Respiratory Innovation Summit
-
04 May 2023 | Lassen Therapeutics Appoints Maria Fardis, PhD, MBA, as Chief Executive Officer
- Industry veteran Dr. Fardis to succeed current CEO Mark Barrett to lead Lassen in its next phase of growth and ongoing advancement of clinical programs
-
- Anti-IL18BP antibodies inhibit tumor growth in a mouse syngeneic tumor model
- Inhibition of IL18BP/IL18 binding releases immune-stimulatory IL18 to mediate a proinflammatory response in cancer
- Anti-human IL-18BP is a promising novel approach for cancer immunotherapy
-
28 September 2022 | Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody
- LASN01 targets the immunological drivers of fibrosis
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- Preclinical data support best-in-class potential of LASN01
-
San Diego, CA, June 15, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado. The data build upon the results in models of lung fibrosis recently presented at the American Thoracic Society (ATS) conference in May.
-
San Diego, CA, May 26, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado, June 12-16, 2022.
-
- LASN01 is a potent inhibitor of IL-11 signaling
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- LASN01 is rapidly advancing toward clinical evaluation
-
- Lassen selected for oral presentation at ATS scientific sessions and will be featured at the ATS Respiratory Innovation Summit
- Lassen SAB member Cory Hogaboam, Ph.D. from Cedars-Sinai, to present data on IL-11 in idiopathic pulmonary fibrosis at ATS scientific sessions
-
18 November 2021 | Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer
Dr. Arora brings deep expertise in innovative biopharmaceutical development and experience in inflammation and immunology
-
San Diego, CA, October 07, 2021 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of a highly experienced industry executive and recognized clinical thought leaders to its team.
-
Goal is to generate proof of principle and mechanistic understanding of the efficacy of antibodies targeting IL-11 receptor in idiopathic pulmonary fibrosis
San Diego, CA, March 25, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect of monoclonal antibodies that block this signaling in preclinical models.
-
Goal is to demonstrate proof of principle in targeting IL-11 receptor as a potential treatment of primary tumors and metastatic lesions
San Diego, CA, February 9, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia. The collaboration will study the role of IL-11 signaling and assess the potential of monoclonal antibodies that block IL-11 signaling in preclinical models of triple negative breast cancer.
-
15 December 2020 | Lassen Therapeutics Announces Formation of Scientific Advisory Board
San Diego, CA, December 16, 2020 – Lassen Therapeutics, a biotech company developing innovative antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced the formation of its scientific advisory board. Lassen’s lead molecule, LASN01, is a best-in-class monoclonal antibody targeting the interleukin-11 (IL-11) receptor. The newly formed SAB will work closely with Lassen’s leadership team to further advance research and development of the company’s innovative pipeline.
-
San Diego, CA, June 17, 2020 – Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. The Series A financing was led by Frazier Healthcare Partners (Frazier) with participation from Alta Partners and Longwood Fund.
> Full Story
Toggle navigation